The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.

Serum Institute of India is planning to introduce chikungunya and monkeypox vaccines in about a year and a half and a dengue vaccine in approximately three years. The company is focusing on vaccine ...

A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022. The study evaluated vaccine ...

Dr. Lulu Bravo, a prominent vaccinologist and vaccine advocate, has been vocal in dispelling common misconceptions surrounding the dengue vaccine. With decades of experience in vaccine development ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

The Pan American Health Organization (PAHO) has issued an epidemiological alert regarding the increased risk of dengue ...

Introduction State of the Art Dengue Vaccine Development Challenges in Dengue Vaccine Development Emerging Opportunities for Advancing Dengue Vaccine References State of the Art Dengue Vaccine ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention ...

It's a big, germy world out there. If you want to travel with peace of mind, learn the basics of vaccines, illnesses, and ...

So with that in mind, after COVID, I sort of focused our capex and partnerships with various companies to make vaccines for malaria, dengue, chikungunya, and yellow fever. Those other vaccines are ...